JP2024532263A - Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法 - Google Patents

Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法 Download PDF

Info

Publication number
JP2024532263A
JP2024532263A JP2024512007A JP2024512007A JP2024532263A JP 2024532263 A JP2024532263 A JP 2024532263A JP 2024512007 A JP2024512007 A JP 2024512007A JP 2024512007 A JP2024512007 A JP 2024512007A JP 2024532263 A JP2024532263 A JP 2024532263A
Authority
JP
Japan
Prior art keywords
antagonist
seq
baseline
subject
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512007A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023028468A5 (https=
JP2024532263A5 (https=
Inventor
アシッシュ・バンサル
ニール・グラハム
モハメッド・カマル
マシュー・ピー・コスロスキ
マルチェッラ・ラディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024532263A publication Critical patent/JP2024532263A/ja
Publication of JPWO2023028468A5 publication Critical patent/JPWO2023028468A5/ja
Publication of JP2024532263A5 publication Critical patent/JP2024532263A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024512007A 2021-08-23 2022-08-23 Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法 Pending JP2024532263A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163236035P 2021-08-23 2021-08-23
US63/236,035 2021-08-23
US202263297908P 2022-01-10 2022-01-10
US63/297,908 2022-01-10
US202263319500P 2022-03-14 2022-03-14
US63/319,500 2022-03-14
US202263341948P 2022-05-13 2022-05-13
US63/341,948 2022-05-13
PCT/US2022/075311 WO2023028468A1 (en) 2021-08-23 2022-08-23 Methods for treating atopic dermatitis by administering an il-4r antagonist

Publications (3)

Publication Number Publication Date
JP2024532263A true JP2024532263A (ja) 2024-09-05
JPWO2023028468A5 JPWO2023028468A5 (https=) 2025-09-01
JP2024532263A5 JP2024532263A5 (https=) 2025-09-01

Family

ID=83280357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512007A Pending JP2024532263A (ja) 2021-08-23 2022-08-23 Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法

Country Status (9)

Country Link
US (1) US20230167171A1 (https=)
EP (1) EP4392450A1 (https=)
JP (1) JP2024532263A (https=)
KR (1) KR20240049351A (https=)
AU (1) AU2022333073A1 (https=)
CA (1) CA3227014A1 (https=)
IL (1) IL310962A (https=)
MX (1) MX2024002072A (https=)
WO (1) WO2023028468A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
WO2025088063A2 (en) * 2023-10-24 2025-05-01 Sanofi Systems and methods for monitoring a medicament dosing schedule

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
ES2983475T3 (es) * 2016-02-19 2024-10-23 Regeneron Pharma Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN112010977B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
IL296214A (en) 2020-03-27 2022-11-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
CN114555639B (zh) 2020-09-10 2023-12-12 舒泰神（北京）生物制药股份有限公司 特异性识别白细胞介素-4受体α的抗体及其用途
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
KR20230123993A (ko) 2020-12-23 2023-08-24 누맙 세러퓨틱스 아게 Il-31에 결합하는 항체 가변 도메인

Also Published As

Publication number Publication date
AU2022333073A1 (en) 2024-04-04
WO2023028468A1 (en) 2023-03-02
KR20240049351A (ko) 2024-04-16
MX2024002072A (es) 2024-05-20
CA3227014A1 (en) 2023-03-02
US20230167171A1 (en) 2023-06-01
IL310962A (en) 2024-04-01
EP4392450A1 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
JP7736667B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
JP2024038234A (ja) Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP7164530B2 (ja) Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
US20230102151A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
JP2019531273A (ja) Ｉｌ−４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
TW202432598A (zh) 藉由投予il-4r拮抗劑治療手足皮膚炎的方法
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
CN117715938A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
RU2828020C2 (ru) Способы лечения атопического дерматита посредством введения антагониста il-4r
KR102955533B1 (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
KR20260056325A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250822